ArticleJournal of lipid research2015
The glycosylation-dependent interaction of perlecan core protein with LDL: implications for atherosclerosis.
Article in Journal of lipid research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- ANGPTL3 regulates the peroxisomal translocation of SmarcAL1 in response to cell growth states.Scientific reports · 2025Article
- Serum N-glycomic profiling identifies candidate biomarker panels for assessing coronary artery stenosis severity.Heliyon · 2024Article
- Chromatin regulator SMARCAL1 modulates cellular lipid metabolism.Communications biology · 2023Article
- Thirty-Five-Year History of Desialylated Lipoproteins Discovered by Vladimir Tertov.Biomedicines · 2022Review
- The Impact of Dietary Diversity, Lifestyle, and Blood Lipids on Carotid Atherosclerosis: A Cross-Sectional Study.Nutrients · 2022Article
- Extracellular matrix dynamics in vascular remodeling.American journal of physiology. Cell physiology · 2020Review
- Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation.Frontiers in immunology · 2020Review
- The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- A cynomolgus monkey model of carotid atherosclerosis induced by puncturing and scratching of the carotid artery combined with a high-fat diet.Experimental and therapeutic medicine · 2018Article
- Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolism with dynamic changes in adipose tissue and skeletal muscle.Scientific reports · 2018Article
- Analysis of Apolipoprotein B Protein of Circulating Multiple-Modified Low-Density Lipoprotein.The International journal of angiology : official publication of the International College of Angiology, Inc · 2017Article
- A current view of perlecan in physiology and pathology: A mosaic of functions.Matrix biology : journal of the International Society for Matrix Biology · 2017Review
- Lipid composition of circulating multiple-modified low density lipoprotein.Lipids in health and disease · 2016Article
- Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.Advanced drug delivery reviews · 2016Review
- Carbohydrate composition of circulating multiple-modified low-density lipoprotein.Vascular health and risk management · 2016Article
- Current strategies and findings in clinically relevant post-translational modification-specific proteomics.Expert review of proteomics · 2015Review
- Proteoglycan form and function: A comprehensive nomenclature of proteoglycans.Matrix biology : journal of the International Society for Matrix Biology · 2015Review
- The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.Connective tissue research · 2015Review
- Macrophages bind LDL using heparan sulfate and the perlecan protein core.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Perlecan is a major heparan sulfate (HS) proteoglycan in the arterial wall. Previous studies have linked it to atherosclerosis. Perlecan contains a core protein and three HS side chains. Its core protein has five domains (DI-DV) with disparate structures and DII is highly homologous to the ligand-binding portion of LDL receptor (LDLR). The functional significance of this domain has been unknown. Here, we show that perlecan DII interacts with LDL. Importantly, the interaction largely relies on O-linked glycans that are only present in the secreted DII. Among the five repeat units of DII, most of the glycosylation sites are from the second unit, which is highly divergent and rich in serine and threonine, but has no cysteine residues. Interestingly, most of the glycans are capped by the negatively charged sialic acids, which are critical for LDL binding. We further demonstrate an additive effect of HS and DII on LDL binding. Unlike LDLR, which directs LDL uptake through endocytosis, this study uncovers a novel feature of the perlecan LDLR-like DII in receptor-mediated lipoprotein retention, which depends on its glycosylation. Thus, perlecan glycosylation may play a role in the early LDL retention during the development of atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.